JPRN-jRCT2080221534
Unknown
Phase 2
A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma
Kyowa Hakko Kirin Co., Ltd.0 sites100 target enrollmentAugust 8, 2011
ConditionsAsthma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Kyowa Hakko Kirin Co., Ltd.
- Enrollment
- 100
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Uncontrolled asthma requiring medium\-dose or high\-dose ICS plus LABA
- •\- History of \=\> 2 but \=\< 6 documented asthma exacerbations in the 12 months that required use of a systemic corticosteroid burst
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthmaDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000178JEIL-KIRIN PHARMACEUTICAL INC.100
Active, not recruiting
Phase 1
A Phase II, double blind, placebo controlled, dose-ranging study in patients with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1 Level: LLT Classification code 10019979EUCTR2005-005863-26-GBTakeda Global Research & Development Centre (Europe) Ltd
Active, not recruiting
Not Applicable
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1Level: LLTClassification code 10019979EUCTR2005-005863-26-DETakeda Europe R&D Centre Ltd400
Active, not recruiting
Not Applicable
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.EUCTR2005-005863-26-NLTakeda Europe R&D Centre Ltd400
Active, not recruiting
Not Applicable
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1Level: LLTClassification code 10019979EUCTR2005-005863-26-CZTakeda Europe R&D Centre Ltd400